[Relationship between PAI-1 gene 4G/5G polymorphism and clinical profile of IgA nephropathy].
It is clear that PAI-1 is a very important factor inhibiting extracellular matrix (ECM) degradation in the pathology process of IgA nephropathy (IgAN), so we design to investigate the relationship between PAI-1 promoter 4G/5G polymorphism and IgAN pathogenesis and progression. Clinical baseline data such as blood pressure, urinary protein excretion, serum profile, and extent of renal tissue damage at the time of renal biopsy were collected. The genotypes of PAI-1 were profiled by PCR-RFLP. (1) The distributions of genotype 4G 4G, 4G5G, 5G5G in PAI-1 gene promoter showed no significant difference between the IgAN group (0.33, 0.19, 0.48) and control group (0.3, 0.23, 0.47; chi-square =1.63, P>0.05); (2) There is an increasing frequency of 4G4G homozygote in the IgAN group who had severe pathology change proved by biopsy (0.39 vs 0.28; chi-square =7.86, P<0.05); in the patients group,the ones who carried 4G4G genotype got lower Ccr than 4G5G genotype cases did (P<0.05). The data here suggest that the 4G/5G polymorphism of PAI-1 is not a risk factor in IgAN etiology, but may facilitate the process of IgAN to end stage renal disease.